PRECIGEN, INC. Debt Securities, Available-for-sale, Amortized Cost
PRECIGEN, INC. (PGEN) had Debt Securities, Available-for-sale, Amortized Cost of $22.40 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $22.40M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $49.27M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $70.13M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $109.30M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $22.40M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $49.27M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $70.13M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $109.30M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $45.98M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $74.92M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $68.38M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $3.89M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $10.21M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $27.31M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $55.31M 10-K · filed 2025-03-19 | |
| 2023-09-30 | $69.10M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $79.28M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $102.31M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $51.85M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $63.50M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $84.67M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $102.87M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $121.13M 10-K · filed 2023-03-06 | |
| 2021-09-30 | $139.64M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $164.03M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $181.98M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $48.31M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $85.27M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $86.01M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $110.75M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $9.25M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $45.27M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $67.60M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $75.10M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $119.67M 10-K · filed 2020-03-02 | $119.75M 10-K · filed 2019-03-01 |
| 2018-09-30 | $164.26M 10-Q · filed 2018-11-08 | |
| 2017-12-31 | $6.28M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $44.52M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $92.90M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $135.49M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $180.68M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $210.89M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $165.91M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $190.18M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $208.49M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $226.84M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $67.37M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $91.44M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $115.57M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $149.65M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $174.48M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $152.88M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $188.54M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $217.76M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $95.47M 10-Q/A · filed 2013-10-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |